62 - Special Session - The Tried, The True, & The New in Ocular Surface Disease

Disclosure(s):

Paul M. Karpecki, OD: AbbVie/Allergan: Consulting Fees (); AI Optics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aramis: Advisory Committee/Board Member (), Consulting Fees (); Atlas Ocular: Consulting Fees (); Azura: Consulting Fees (); Barti: Consulting Fees (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); BioTissue: Advisory Committee/Board Member (), Consulting Fees (); Blephex: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder Healthcare/Hilco: Advisory Committee/Board Member (), Consulting Fees (); Bruno Vision Care: Consulting Fees (); Cambium: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Danelli Ocular Creations: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Dompe: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Essilor: Consulting Fees (); Eyedaptec: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Eyedetec: Consulting Fees (); Harrow: Consulting Fees (), Researcher (grant funding or other support) (), Speaker's Bureau (honoraria or other compensation) (); Healthe: Advisory Committee/Board Member (), Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Hui.AI: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); iCare: Consulting Fees (); iOR Holdings: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Iveena: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); LeGrande: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); LenTechs: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Lexitas: Advisory Committee/Board Member (), Consulting Fees (); Lubris: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Mallinckrodt: Speaker's Bureau (honoraria or other compensation) (); Mati Therapeutics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Neurolens: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Oasis Medical: Consulting Fees (); Oculus: Consulting Fees (); OcuSoft: Consulting Fees (); Omega Ophthalmics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Ophthalmic Resources: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Orasis: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Percept: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); RegenerEyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Rendia: Consulting Fees (); RxSight: Consulting Fees (); Science Based Health: Consulting Fees (); Scope: Consulting Fees (); Sentiss: Consulting Fees (); Sight Sciences: Consulting Fees (); Signal 12: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Silk Tears: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Stuart Pharmaceuticals: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Surface Pharma: Advisory Committee/Board Member (), Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Sydnexis: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); TecLens: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Thea Laboratories: Consulting Fees (); Topcon: Consulting Fees (); Vision Path: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Vital Tears: Consulting Fees ()

Walt Whitley, OD, MBA, FAAO: AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()

Cecelia Koetting, OD: AbbVie/Allergan: Consulting Fees (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Consulting Fees (), Independent Contractor (including contracted research) (), Speaker's Bureau (honoraria or other compensation) (); Blephex: Consulting Fees (); bruder: Consulting Fees (); Dompe: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Glaukos: Consulting Fees (); harrow: Speaker's Bureau (honoraria or other compensation) (); Movu: Advisory Committee/Board Member (), Consulting Fees (); Myze: Consulting Fees (); nulids: Consulting Fees (); Topcon: Consulting Fees (); viatris: Speaker's Bureau (honoraria or other compensation) ()

Janelle Davison, OD: Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Orasis: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Scope Eye Care: Consulting Fees (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); twenty twenty beauty: Advisory Committee/Board Member (); Viatris: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); virtual visual field: Consulting Fees ()